Success Metrics

Clinical Success Rate
73.0%

Based on 116 completed trials

Completion Rate
73%(116/159)
Active Trials
60(21%)
Results Posted
65%(75 trials)
Terminated
43(15%)

Phase Distribution

Ph early_phase_1
6
2%
Ph not_applicable
29
10%
Ph phase_4
1
0%
Ph phase_2
131
46%
Ph phase_1
66
23%
Ph phase_3
33
12%

Phase Distribution

72

Early Stage

131

Mid Stage

34

Late Stage

Phase Distribution266 total trials
Early Phase 1First-in-human
6(2.3%)
Phase 1Safety & dosage
66(24.8%)
Phase 2Efficacy & side effects
131(49.2%)
Phase 3Large-scale testing
33(12.4%)
Phase 4Post-market surveillance
1(0.4%)
N/ANon-phased studies
29(10.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

67.1%

116 of 173 finished

Non-Completion Rate

32.9%

57 ended early

Currently Active

60

trials recruiting

Total Trials

284

all time

Status Distribution
Active(78)
Completed(116)
Terminated(57)
Other(33)

Detailed Status

Completed116
Terminated43
Recruiting37
unknown33
Active, not recruiting23
Not yet recruiting18

Development Timeline

Analytics

Development Status

Total Trials
284
Active
60
Success Rate
73.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (2.3%)
Phase 166 (24.8%)
Phase 2131 (49.2%)
Phase 333 (12.4%)
Phase 41 (0.4%)
N/A29 (10.9%)

Trials by Status

withdrawn145%
active_not_recruiting238%
unknown3312%
completed11641%
not_yet_recruiting186%
terminated4315%
recruiting3713%

Recent Activity

Clinical Trials (284)

Showing 20 of 284 trialsScroll for more
NCT03970447Phase 2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Recruiting
NCT06205485Phase 3

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Recruiting
NCT03488693Phase 3

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Recruiting
NCT03514069Phase 1

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

Completed
NCT06194448Phase 2

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Active Not Recruiting
NCT03789097Phase 1

Vaccination With Flt3L, Radiation, and Poly-ICLC

Completed
NCT07038629Phase 2

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

Recruiting
NCT04846309Phase 1

Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy

Recruiting
NCT06234748Phase 2

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

Active Not Recruiting
NCT06300463Phase 2

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Recruiting
NCT04550260Phase 3

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

Active Not Recruiting
NCT07580339Phase 2

Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer

Not Yet Recruiting
NCT03337698Phase 1

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Terminated
NCT03554707Early Phase 1

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Withdrawn
NCT04084431Not Applicable

Supportive Care With or Without Repeated Whole Brain Radiotherapy in Patients With Recurrent Brain Metastases

Withdrawn
NCT03482102Phase 2

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Active Not Recruiting
NCT01871766Phase 2

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Active Not Recruiting
NCT05491512Phase 2

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Recruiting
NCT07540390Phase 3

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

Not Yet Recruiting
NCT02917421Phase 1

Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations

Active Not Recruiting

Drug Details

Intervention Type
RADIATION
Total Trials
284